Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/2/2025

Thrombolytic Therapy in Pulmonary Embolism

Comparison of Mechanisms and Administration

  • Tenecteplase has a longer half-life than alteplase, allowing for bolus administration, and is considered superior to alteplase for intermediate-risk pulmonary embolism due to its more favorable safety profile and comparable efficacy 1, 2
  • Alteplase requires a 2-hour infusion, while tenecteplase can be administered as a single bolus, offering greater convenience in emergency settings 2, 3

Efficacy Comparison

  • The American College of Cardiology recommends tenecteplase as a first-line treatment for intermediate-risk pulmonary embolism, as it decreased the frequency of hemodynamic collapse compared to anticoagulation alone in the PEITHO trial (1.6% versus 5.0%; P=0.002) 1
  • Tenecteplase showed improved right ventricular function in patients with intermediate-risk pulmonary embolism in the Becattini et al. study 4, 5

Safety Profile

  • Tenecteplase was associated with a 2% incidence of hemorrhagic stroke and increased major non-intracranial bleeding in the PEITHO trial 2

Clinical Decision Algorithm

  • For intermediate-risk pulmonary embolism, tenecteplase should be considered first-line when thrombolysis is indicated, due to its convenient single-bolus administration 1, 2
  • The American Heart Association recommends alteplase as the standard FDA-approved agent for massive pulmonary embolism (100mg over 2 hours) 3

Special Considerations

  • Ultrasound-assisted catheter-directed thrombolysis with alteplase has shown efficacy in reducing RV/LV ratio in intermediate-risk pulmonary embolism patients 6
  • The European Society of Cardiology recommends initiating thrombolysis within 48 hours of symptom onset for greatest benefit, though it may still be useful up to 6-14 days 2